Drug Update · Endocrinology

Tirzepatide: Mounjaro vs Zepbound — Indications and Dosing Differences

July 10, 2026

SURMOUNT-4 primary result

Mean percent weight change week 36 to 88: -5.5% with tirzepatide vs 14.0% with placebo (difference -19.4%; 95% CI -21.2% to -17.7; P < .001) [1]

SURMOUNT-4 maintenance proportion

89.5% on tirzepatide maintained ≥80% lead-in weight loss vs 16.6% on placebo [1]

MOUNJARO indication

Adjunct to diet/exercise to improve glycemic control in adults and pediatric patients 10+ with type 2 diabetes mellitus [9][10]

MOUNJARO dosing (label)

Start 2.5 mg weekly; escalate after 4 weeks to 5 mg and by 2.5 mg increments up to 15 mg (adult); pediatric max 10 mg [9][10]

ZEPBOUND indication

Reduce excess body weight and maintain weight reduction in adults with obesity or overweight with comorbidity; treat moderate to severe OSA in adults with obesity [7][11]

ZEPBOUND dosing (label)

Start 2.5 mg weekly for 4 weeks; increase by 2.5 mg increments after ≥4 weeks. Maintenance: 5, 10, or 15 mg weekly for weight reduction; 10 or 15 mg weekly for OSA; max 15 mg [7][11]

Clinical Perspective

This comparison affects endocrinologists, primary care clinicians, obesity specialists, and sleep medicine clinicians managing adults with type 2 diabetes, obesity, or obstructive sleep apnea, and pediatric endocrinologists treating patients 10 years and older with T2DM as referenced in the MOUNJARO label ^[3]^[2]^[5]. The source‑confirmed data and labels support using MOUNJARO for glycemic control in type 2 diabetes (including pediatric 10+), and using ZEPBOUND for physician‑supervised weight reduction/maintenance and for OSA in adults with obesity, with overlapping initiation/escalation schedules but different labeled maintenance targets and population labels ^[3]^[2]^[5]. An unanswered clinical question is whether weight‑maintenance benefits observed with tirzepatide in adults without diabetes (SURMOUNT-4) translate fully to patients who have type 2 diabetes treated under MOUNJARO labeling?

Dr. Amit Desai · Endocrinology

MOUNJARO (tirzepatide) is labeled as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus; the recommended initiation dose is 2.5 mg subcutaneously once weekly with stepwise escalation to a maximum adult dose of 15 mg weekly ^[3]^[4]. ZEPBOUND (tirzepatide) is labeled for weight reduction and long-term weight‑maintenance in adults with obesity or adults with overweight and a weight‑related comorbidity, and for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity; ZEPBOUND’s starting dose and escalation schedule are 2.5 mg once weekly with maintenance options including 5 mg, 10 mg, or 15 mg once weekly for weight reduction and 10 mg or 15 mg once weekly for OSA (maximum 15 mg) ^[2]^[5]. Clinicians should consult current prescribing information for complete dosing guidance.

Clinical Context

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that prolongs action through a C20 fatty diacid enabling albumin binding, and is available under multiple branded presentations from Eli Lilly and Company ^[5]^[6]. The molecule is marketed in distinct regulatory indications: MOUNJARO is approved for glycemic control in type 2 diabetes mellitus, including pediatric use from age 10 years, whereas ZEPBOUND is approved specifically as a weight-reduction and long-term weight‑maintenance therapy and for OSA in adults with obesity ^[3]^[2]^[5]. Labels for both products include boxed warnings about rodent thyroid C‑cell tumors and contraindications in patients with a personal or family history of medullary thyroid carcinoma or MEN 2; both labels also list gastrointestinal adverse reactions among the most common adverse events ^[3]^[2]^[5]. Evidence for weight outcomes includes tirzepatide randomized trials in obesity and a randomized-withdrawal maintenance trial that evaluated continued versus withdrawn treatment for maintenance of weight loss ^[1]^[5].

Key Findings

The SURMOUNT-4 randomized withdrawal phase 3 trial evaluated continued tirzepatide versus placebo for maintenance of weight reduction in adults with obesity or overweight (excluding diabetes). After a 36-week open-label tirzepatide lead-in, 670 participants were randomized 1:1 to continue tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks; the mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide vs 14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7]; P < .001) ^[1].
In SURMOUNT-4, 89.5% of participants receiving tirzepatide at week 88 maintained at least 80% of the initial lead-in weight loss versus 16.6% receiving placebo (P < .001), and the overall mean weight reduction from baseline to week 88 was 25.3% for tirzepatide and 9.9% for placebo ^[1].
Regulatory labels specify differing primary indications and permitted dosing ranges: MOUNJARO’s U.S. approval is for glycemic control in T2DM with initiation at 2.5 mg once weekly, escalation after 4 weeks to 5 mg and further 2.5 mg increments as needed up to 15 mg in adults (pediatric maximum 10 mg) ^[3]^[4]; ZEPBOUND’s U.S. approval is for weight reduction/maintenance and OSA with the same 2.5 mg weekly initiation and 2.5 mg escalation steps but with maintenance dosing explicitly listed as 5 mg, 10 mg, or 15 mg for weight reduction and 10 mg or 15 mg for OSA (maximum 15 mg) ^[2]^[5]. Clinicians should consult current prescribing information for complete dosing guidance.

Safety & Tolerability

MOUNJARO: The most common adverse reactions reported in ≥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain ^[3]^[4].
ZEPBOUND: The most common adverse reactions reported in ≥5% of patients treated with ZEPBOUND include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease ^[2]^[5].
SURMOUNT-4 safety summary: the trial reported that the most common adverse events were mostly mild to moderate gastrointestinal events, which occurred more commonly with tirzepatide than with placebo ^[1].

Study Design

The SURMOUNT-4 trial was a phase 3, randomized withdrawal clinical trial conducted at 70 sites with a 36‑week open‑label tirzepatide lead‑in followed by a 52‑week double‑blind, placebo‑controlled period; 783 participants entered the lead‑in (maximum tolerated once‑weekly 10 or 15 mg), and 670 completed the lead‑in and were randomized 1:1 to continue tirzepatide (n = 335) or switch to placebo (n = 335) for the randomized period; participants had BMI ≥30 or ≥27 with a weight‑related complication and the trial excluded patients with diabetes ^[1]. Clinicians should consult current prescribing information for full dosing guidance. Regulatory prescribing information for MOUNJARO and ZEPBOUND describes indications, dosing initiation/escalation, maintenance dosing options, boxed warnings, and adverse reaction profiles in U.S. labeling ^[3]^[2]^[5].

FAQ

What is tirzepatide (MOUNJARO and ZEPBOUND) approved for?

MOUNJARO (tirzepatide) is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ZEPBOUND (tirzepatide) is approved, in combination with a reduced‑calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight who have at least one weight‑related comorbidity, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

How does tirzepatide work?

Tirzepatide is a dual glucose‑dependent insulinotropic polypeptide (GIP) receptor and glucagon‑like peptide‑1 (GLP‑1) receptor agonist. The molecule contains a C20 fatty diacid that promotes albumin binding and prolongs half‑life; it binds and activates both GIP and GLP‑1 receptors, receptors that are involved in regulating appetite, caloric intake, and glucose‑dependent insulin secretion.

What is the dose?

Both labels specify initiating tirzepatide at 2.5 mg injected subcutaneously once weekly for 4 weeks, with escalation in 2.5 mg increments after at least 4 weeks until a maintenance dose is reached. MOUNJARO’s recommended adult escalation can reach up to 15 mg once weekly (pediatric maximum 10 mg for patients 10 years and older). ZEPBOUND lists maintenance options for weight reduction of 5 mg, 10 mg, or 15 mg once weekly and for OSA 10 mg or 15 mg once weekly, with a maximum recommended dosage of 15 mg once weekly. Clinicians should consult current prescribing information for complete dosing guidance.

What are the side effects?

Common adverse reactions listed in the MOUNJARO label reported in ≥5% of patients include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. ZEPBOUND labeling lists common adverse reactions reported in ≥5% of patients that include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease. Both labels include warnings about risk of rodent thyroid C‑cell tumors and contraindicate use in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. If symptoms suggestive of pancreatitis or severe gastrointestinal events occur, evaluation and management per the product label are recommended.

Tirzepatide: Mounjaro vs Zepbound — Indications and Dosing Differences

Direct Clinical Takeaway & Evidence Summary

Tirzepatide: Mounjaro vs Zepbound — Indications and Dosing Differences

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Endocrinology in your inbox.

Related Clinical Updates

FDA Approves denosumab-adet (Ponlimsi) as Interchangeable Biosimilar to Prolia

Orforglipron (FOUNDAYO) FDA Approved for Obesity; 11.2% vs 2.1% Mean Weight Change in ATTAIN-1

GLP-1 Receptor Agonists Beyond Glycemia: Cardiovascular, Weight and Mechanistic Evidence for Clinicians

Verified HCP Portal